|
Immunobiological agent for treating urinary bladder cancer and method of application thereof Group of inventions relates to medicine and deals with an immunobiological agent for treating urinary bladder cancer, based on BCG vaccine, including a peptidoglycan fragment, which contains diaminopimelic acid as a part of its structure. The group of inventions also deals with a method of applying the claimed immunobiological agent for the treatment of urinary bladder cancer. |
|
Attenuated strain bacillus anthracis for developing means of specific prevention of anthrax Strain of B. anthracis 363/11 is deposited in the collection of strains of microorganisms of State Scientific Institution of Russian National Research Institute of Veterinary Virology and Microbiology of Russian Agricultural Academy No. 363. The strain is made for developing the means of specific prevention of anthrax. |
|
|
Presented vaccine comprises the formalin-inactivated leukocidin-exotoxin obtained from production strain Fusobacterium necrophorum "0-1" Russian Research Institute of Experimental Veterinary Medicine ,1-10% inactivated bacterial mass of the said strain containing 7.0-7.7 billion cells per 1 cm3, glycerol and a mixture of mineral oil "Markol-52" and emulsifier taken in weight ratios of 1:(0.9-1.1), and also the suspension of live spores of splenic fever vaccine strain 55 Russian Research Institute of Veterinary Virology and Microbiology in saline, and adjuvant. The method of production of the vaccine comprises cultivation of the strain Fusobacterium necrophorum "0-1" RRIEVM, its inactivation with formalin, isolation of bacterial mass from the culture medium by centrifugation, isolation from the culture medium of exotoxin - leukocidin, its purification and concentration by ultrafiltration on hollow fibres, adding the suspension of live spores of the splenic fever vaccine strain 55-RRIVVM and saponin, and adding of 1-10% inactivated bacterial mass of strain Fusobacterium necrophorum "0-1" RRIEVM, glycerine and mixture of mineral oil "Markol-52" and emulsifier. |
|
|
Associated vaccine for prevention of anthrax and necrobacillosis in animals Invention refers to veterinary science and biotechnology, and concerns preparing an associated vaccines for prevention of anthrax and necrobacillosis in animals. The characterized vaccine contains the following ingredients in proportions, wt %: a suspension of living spores of the anthrax vaccine strain 55-VNIIVViM (All-Russian Research Institution of Virology and Microbiology) with the initial concentration of (5-5.2)X107 in physiologic saline 1 cm3 - 1.0-1.2; -saponin - 1.5-2.1; -formalin-inactivated leukocidin - exotoxin with molecular weight 18-20 kDa of the strain of Fusobacterium necrophorum "0-1" VIEV (All-Russian Institution of Experimental Virology with the protein content of 5.5- 6 mg % adsorbed in 12-15% aluminium hydroxide taken in the final concentration of 1.8-2.0% pre-suspended in glycol buffer with pH 8.4-8.6 - the rest. |
|
|
Method for producing diagnostic anthrax allergen Method provides recovery of a diagnostic anthrax allergen directly from a concentrated suspension of vegetative cells of a vaccine strain Bac. anthracis STI-1. The strain is grown on a nutrient medium based on a muriatic hydrolyzate of a fish flour by deep cultivation. The produced bacterial mass is washed in a separator to produce the concentrated suspension of vegetative cells. An allergenic protein fraction is recovered by alkaline hydrolysis, and the prepared hydrolyzate is fractioned. A protein allergen fraction is recovered from a supernatant of the recovered fraction by fractioning with an acetic acid solution; further the precipitation containing an end product is dissolved, dialyzed to produce a purified anthrax protein allergen. The preparation is presented in liquid and lyophilised forms. |
|
|
Method for increase of melioidosis antigens protectivity by cytokines Invention is related to the field of medicine, in particular to microbiology and immunology and may be used in development of vaccine against melioidosis. Substance of method consists in the fact that animals are immunised with surface melioidosis complex, which consists of antigen 6 (AG6) and antigen d, which is injected to animals subcutaneously, twice, with interval of 10 days, in doses of 30 mcg by protein for mice or 150 mcg for rats. Simultaneously with primary immunisation recombinant interferon-γ - ingaron is injected in doses 8 ME for mice or 120 ME for rats, and in case of secondary immunisation, recombinant interleukin-2 - roncoleukin in doses of 0.6 mcg for mice or 10 mcg for rats, besides cytokines are injected to animals subcutaneously, daily, simultaneously with immunisation and in the next 2 days. In 21 days after primary immunisation animals are infected with 4-32 LD50 of highly virulent strain 100 of melioidosis causative agent, in 30 days after infection parametres of animal lethality are identified. |
|
|
Invention refers to medicine, particularly to microbiology and immunology and can be used for immunoprophylaxis of pseudocholera. The method involves antigen pretreatment to mice followed by infection and estimating level of protectivity. Antigens Burkholderia pseudomallei are chosen of superficial antigenic fractions: D, C, F, J, H. Herewith the antigen solution in amount 1.5 ml is mixed with phosphatidyl choline approximately 40 mg and cholesterol in the ratio 7:3 to produce liposomes. |
|
|
Method of obtaining of anthracic protective antigen Plating of the vaccine strain on a sterile nutrient medium with sodium bicarbonate. Thus administer sodium bicarbonate into a nutrient medium throughout an exponential growth phase at 6-8 hours of the vaccine strain planting. After the planting process termination allocation, concentration and sterilisation of a protective antigen is performed on the equipment of ultra-and microstraining. |
|
|
Immunogenic composition (versions) based on recombinant intracellular pathogen Presented are immunogenic compositions including recombinant attenuated intracellular pathogens, e.g. Calmette-Guérin bacillus (CGB). Immunogenic composition specifically includes CGB containing sequenced extrachromosomal nucleic acid which includes gene coding large extracellular mycobacteria protein sized 23.5, 30 and/or 32 kDa, thus large extracellular unmerged mycobacteria protein is superexpressed and secreted. Version is immunogenic composition containing recombinant CGB with controlled growth. Introduction of immunogenic compositions in mammal organism is associated with superexpression and secretion of specified proteins causing immune response of organism to introduced antigene. |
|
Proteins causing alternated immunogenic response and methods for their preparing and using Invention relates to a variant of protein subtilysine from Bacillus amyloliquiefaciens with change Y217L and comprising T-cellular epitope. This T-cellular epitope of indicated variant comprises one or some amino acid changes chosen from group consisting of residues corresponding to positions: 76, 79 and 122 wherein indicated subtilysine variant has optionally change at one or some following positions: 3, 31, 40, 41, 46, 47, 48, 50, 76, 101, 104, 107, 111, 128, 147, 154, 181, 182, 183, 185, 206, 215, 218, 238, 247, 248, 250, 254, 258 and 262. Also, invention relates to DNA molecules that encode subtilysine variants, host-cells containing this DNA, and to compositions used in skin care and containing indicated subtilysine variants. Invention provides preparing subtilysine variants that elicit reduced immunogenic response in human as compared with the parent subtilysine. |
|
Method for preparing nontoxic anti-anthrax vaccine Invention relates to producing vaccines and describes anti-anthrax vaccine that comprises mutant protein toxin from Bacillus anthracis chosen from mutant PA or mutant LF, or mutant EF or their combinations. Mutations of toxins provide the retained immunogenicity in decreasing the level of their toxicity. For the development of vaccine with reduced reactivity invention proposes recombinant DNA-construction for expression of said protein-toxins. DNA-construction comprises the expressing vector and DNA fragment comprising, in turn, genes encoding the corresponding protein-toxin (PA, LF or EF). Invention describes a method for preparing mutant proteins by using the transformed prokaryotic host. Prepared mutant protein-toxin possessing immunogenic properties and absence of toxicity is used for preparing anti-anthrax vaccine comprising one or more mutant protein-toxins and in combination with protein-toxin PA, LF or EF of wild type. Using the invention provides to develop the safety and effective vaccine against anthrax. |
|
Associated vaccine against anthrax and plague in cattle The suggested vaccine contains suspension of viable spores of anthracic vaccinal strain "55-VNIIBB&M" at initial concentration of 500-700 mln. spores/cu.cm, cultural virus-containing raw material of vaccinal virus of cattle plague of "LT" strain at activity of not less than 7.0 lg TCD50/cu. cm, lactosopeptonic stabilizing agent and distilled water at the following content of components,%: spores of anthracic strain "55-VNIIVV&M" -6.2 - 10.0; cultural raw material of cattle plague virus of "LT" strain -25.0 - 30.0; lactosopeptonic stabilizing agent -48.0 - 50.0; distilled water - the rest. One vaccinal dosage contains about 20-25 mln. anthracic spores and about 4.5-5.5 lg TCD50 of cattle plague virus The suggested vaccine is of high immunogenicity, develops tense immunity in once vaccinated cattle that lasts for 12 mo, not less, moreover, it is areactogenous, safe and stable at storage. |
|
|
Invention relates to a method for preparing an immunogenic polypeptide inducing immune response that represents the protective response against infection with Bacillus anthracis. Proposed immunogenic polypeptide comprises from one to three domains of the full-scale Protective Antigen (PA) from B. anthracis or their variants and at least one of indicated domains represents domain 1 or domain 4 from PA or its variant. These variants of immunogenic polypeptide and full-scale PA are produced as result of expression in E. coli. Also, invention proposes a vector for expression in bacterial cells that comprises nucleic acid encoding abovementioned immunogenic polypeptide. Also, invention the developed method for prophylaxis of infection caused by B. anthracis based on administration of sufficient amount of immunogenic polypeptide. Also, invention proposes a vaccine for prophylaxis of infection caused by B. anthracis that comprises the effective amount of immunogenic polypeptide and a suitable carrier. Invention provides preparing the effective agent used for prophylaxis of infection caused by B. anthracis. |
|
Method for production of immune serum to virulent strain bacillus anthracis antigen Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days). |
Another patent 2550989.